Applying human factors best practices to product development is much more than executing a validation study

Creating safer, more effective and engaging experiences for your customers starts much earlier.

The foundation for great products begins with exploratory research and spans the entire development process.

Explore & understand

Understand the challenges faced by patients, caregivers, and healthcare professionals when interacting with similar products already on the market.

  • We observe intended users of your product in their natural use environments. This helps inform definitions of critical tasks, as well as, provide a better understanding early on for which use-related challenges and risks your product should account.
  • We analyze behavioral data, qualitative feedback, and existing post-market surveillance data to get a comprehensive understanding of barriers to safe and effective use.
  • We inform the development of a robust human factors plan that will minimize the amount of time and effort required to validate your product.

Design & iterate

Get feedback early and often to fix use-related risks while it’s still easy to do so.

  • Rapidly test early design iterations in small sample formative usability tests to mitigate use-related risks.
  • Document updates to the use-related risk analysis (URRA) and progress the HFE report to reflect the evolution of your product’s design as a result of formative evaluations.
  • Refine and finalize definitions for intended users, use environments, and (critical) tasks.
  • As product design approaches production equivalence, shift focus to refinement of research protocols and simulation of use environments in preparation for human factors validation.

Measure & validate

Know where you stand and get the insight you need to focus future development efforts or to document the achievement of objectives.

  • Ensure that intended users, critical tasks, and elements of simulated use are appropriately defined.
  • Conduct thorough root cause analysis of all observed use errors, close calls and operational difficulties to determine if residual use-related risk is acceptable.
  • Validate that your product can be used safely and effectively by its intended users, in its intended use environments, for its intended uses

Management & strategy

It happens that organizations do not have proper medical device development processes in place (because there is rarely need for it) or the organization is large and processes vary from department to department. We support you in getting the task done.

  • We provide consulting and interim management to set up one-time medical device developments according to regulatory needs.
  • We analyze existing processes (or create them). We align them to be more efficient and at the same time fulfill all regulatory requirements.
  • We connect you to international partners worldwide and execute your studies where you don’t have boots on the ground.

Contact information


uintent
Web: www.uintent.com
Email: hello@uintent.com

Go to article: Home | High-Tech Mental Health TreatmentsGo to article: In this issueGo to article: ContentsGo to article: Formacoat Company InsightGo to article: FormacoatGo to article: PSN Labs Go to article: AccumoldGo to article: BriefingGo to article: Industry newsGo to article: Covid-19 executive briefing by GlobalDataGo to article: The medical industry briefingGo to article: uintent Company InsightGo to article: uintentGo to article: Apple RubberGo to article: Custom Wire Company Insight Go to article: Custom WireGo to article: CommentGo to article: Hearing implants market to reach $2.1bn by 2028, post-Covid-19Go to article: Recent hacks highlight importance of strong cybersecurityGo to article: Disposable endoscopes set to disrupt the reusable endoscopes marketGo to article: Will Covid-19 tests with EUA need to seek FDA approval once pandemic passes?Go to article: Covid-19 had a negative impact on general surgery device markets in 2020Go to article: Desert Platforms Company Insight Go to article: Desert PlatformsGo to article: CombinosticsGo to article: Duke Empirical Company Insight Go to article: Duke EmpiricalGo to article: In DepthGo to article: How can AI transform pneumonia diagnosis?Go to article: Using virtual reality to overcome anxious social avoidanceGo to article: Omar Ahmad: medtech’s quest for post-Covid success in 2021Go to article: NightWare vs nightmares: the sleep tech app helping break PTSD patternsGo to article: Just a swipe away: how the NHS plans to offer health records on iPhoneGo to article: Diagnostic imaging: assessing the testicular cancer riskGo to article: Do AI disease prediction models underestimate risk?Go to article: Will 2021 be just as challenging as 2020 for medtech notified bodies?Go to article: HirLan Company InsightGo to article: HirLanGo to article: Ergonomics FactoryGo to article: FISBAGo to article: In DataGo to article: Deals analysisGo to article: The medical industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issueGo to article: AxetrisGo to article: Smiths InterconnectGo to article: mdi ConsultantsGo to article: Omnica